Agenus has unveiled promising new clinical data at the American Society of Clinical Oncology (ASCO) demonstrating how Botensilimab, an innovative cancer immunotherapy, can stimulate immune responses in patients with previously ‘untreatable’ colorectal cancer. The study highlights Botensilimab’s unique mechanism of action, which effectively enhances the body’s immune system to identify and combat cancer cells. This breakthrough offers renewed hope for patients with limited treatment options, showcasing significant tumor reduction and improved survival rates. By targeting specific cancer pathways, Botensilimab provides a novel approach to fighting aggressive colorectal cancers. The ASCO data presentation underscores its role as a potential game-changer in oncology, emphasizing significant advancements in cancer treatment. As researchers continue to explore Botensilimab’s full potential, this development marks a critical step forward in making ‘untreatable’ cancers more manageable.
Stock TitanNew data shows 90% of buyers unable to afford new Brisbane apartments
April 29, 2026
In Brisbane, a startling new statistic reveals that nine out of ten potential buyers are priced out of the city’s new apartment market. With soaring